Navigation Links
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
Date:5/27/2009

putamen but no evidence for transport of this protein to the cell bodies of the degenerating neurons, located in the substantia nigra. In addition to the known cell loss in Parkinson's disease, these findings suggest that deficient axonal transport in degenerating nigrostriatal neurons in advanced Parkinson's disease impaired transport of CERE-120 and/or neurturin from putaminal terminals to nigral cell bodies, reducing the bioactivity of CERE-120. The data were presented today at the American Society of Gene Therapy Meeting in San Diego, CA by Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer.

"While we were disappointed that our initial analysis of the data from this trial did not demonstrate a benefit of CERE-120 in the primary endpoint at 12 months, we are greatly encouraged by both the results of these protocol-prescribed analyses in patients who remained blinded for up to 18 months, as well as by the insight we gained," stated Dr. Bartus. "Collectively, these data suggest that CERE-120 is indeed exerting a unique and potentially important biological effect on the degenerating dopamine neurons in moderately advanced Parkinson's disease patients but that the inability of these neurons to efficiently transport neurturin back to their cell bodies compromises and delays the neurotrophic effects of neurturin in a manner that had not been anticipated. Importantly, we believe that we can overcome the transport problems of these degenerating neurons by modifying the dosing paradigm to also directly target their cell bodies in the substantia nigra with CERE-120."

"We remain optimistic that CERE-120 has the potential to significantly improve the treatment of advanced Parkinson's disease patients," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "The information gained from this initial controlled Phase 2 trial in advanced Parkinson's disease patients has been
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
2. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
5. Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
6. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
7. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
8. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
9. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
10. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
11. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... FL (PRWEB) , ... September 01, 2015 , ... September ... about this disease that affects more than 233,000 men each year in the United ... is the most common non-skin cancer in America, affecting 1 in 7 men. One ...
(Date:9/1/2015)... ... September 02, 2015 , ... The Journal of Pain Research ... the USA ”. , As corresponding author Mr Christopher Malone says “Migraine headache is ... study, we endeavoured to better understand how migraine headaches impact the lives of migraineurs. ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... physical therapy company, is pleased to announce their partnership with Apex Physical ... allows both groups to continue to provide kind, compassionate, and empathetic care to ...
(Date:9/1/2015)... San Diego, CA (PRWEB) , ... September 01, 2015 , ... ... with Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. ... San Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional ...
(Date:9/1/2015)... ... 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) has ... LATINA Style 50 Report that recognizes companies that provide the best career opportunities for ... climbs from number 24 to 21 of the 50 Best Companies for Latinas. The ...
Breaking Medicine News(10 mins):Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Migraine, treatment, comorbidities, and quality of life published by Dove Medical Press 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3
... be in the eye of the beholder, but a new ... in the eye of the beheld. Research published in ... sadder, unhealthier and less attractive than people whose eye whites ... "Red, ,bloodshot, eyes are prominent in medical diagnoses and in ...
... FL (April 7, 2011) -- Deep brain stimulation, a ... percent of patients to stop the medications used to ... surgery, University of South Florida researchers report. "It,s ... of symptom improvement with this treatment option," said Andrew ...
... HealthDay Reporter , WEDNESDAY, April 6 (HealthDay News) -- What you ... heart health in the future, suggests new research. The ... if it,s well within the normal range, the greater your risk ... in the April 7 issue of the New England Journal ...
... 7 (HealthDay News) -- Gaps in care for black and ... as the VA Health Care System improved access to screenings ... disparities persist in control of cholesterol, diabetes and high blood ... performance measures among a national sample of more than 1.2 ...
... A large cohort study following 37,000 teenagers for 17 ... Index (BMI) constitutes a substantial risk factor for obesity-related disorders ... that elevated BMI in adolescence has distinctive relationships with type ... Researchers showed that diabetes is influenced mainly by ...
... Reporter , WEDNESDAY, April 6 (HealthDay News) -- In a ... of heterosexual couples confirms that the risk of transmitting HIV ... cervical fluid. The finding -- that more virus ... to this extent before, said study lead author Dr. Jared ...
Cached Medicine News:Health News:Is beauty found in the whites of the eyes? 'Red eyes' associated with the sad and unattractive 2Health News:Most patients stop drugs for essential tremor after deep brain stimulation surgery 2Health News:Most patients stop drugs for essential tremor after deep brain stimulation surgery 3Health News:Teen Weight Affects Later Heart Disease Risk: Study 2Health News:Teen Weight Affects Later Heart Disease Risk: Study 3Health News:Adolescent body mass index can predict young adulthood diabetes and heart disease 2Health News:Adolescent body mass index can predict young adulthood diabetes and heart disease 3Health News:Amount of HIV in Genital Fluid Linked to Transmission 2
(Date:9/1/2015)... TAIPEI , Sept. 1, 2015 ... (GNTbm) held a press conference in Taipei ... developments in its new Vaucarrin™ platform, a targeted drug ... vehicle. This event was part of a ... Gold NanoTech Inc. (GNT), showcasing GNT,s latest ...
(Date:9/1/2015)... Sept. 1, 2015 Sargas Pharmaceutical Adherence ... and Drug Adherence m Health applications along with ... process of non face-to-face monitoring of twenty minutes ... release of our apps, doctors are now well ... with our ONCHIT certified Physician, Pharmacy and Patient ...
(Date:9/1/2015)... -- Agena Bioscience TM today announced the establishment of ... and financial hub from which many biotech and life science ... mainland China . "The Chinese ... with almost sixty MassARRAY ® Systems installed to date. ... us to expand our reach and foster a high degree ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... 12 Research presented at the American College of ... that an intervention to reduce over-dispensing and waste of ... can result in substantial cost savings. , Medco Health ... of a study that examined the effectiveness and safety ...
... 12 /PRNewswire / -- New research findings ... (SIO) Sixth International Conference in New York show ... complementary and alternative medicine (CAM) using traditional research ... Children,s Hospitals and Clinics of Minnesota (Children,s), presented ...
Cached Medicine Technology:New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 2New Research Shows Over-use of Asthma Rescue Inhalers Substantially Reduced Through Pharmacist-initiated Physician Intervention 3New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Angled 45 degree shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and 6 mm tying platform. Wide serrated handle with polished finish....
Medicine Products: